Arycs Technologies | $24,000,000 | (Mar 13, 2026)
Ezra(2) | $8,000,000 | (Mar 13, 2026)
Freestyle | $10,000,000 | (Mar 13, 2026)
Certified by Founder
Lodge
Altesa BioSciences, Inc.
start up
United States
- Atlanta, GA
- 20/02/2026
- Series B
- $75,000,000
Altesa is an innovative, clinical-stage pharmaceutical company dedicated to preventing and treating the leading cause of COPD and asthma exacerbations -- namely viral respiratory infections -- starting with rhinovirus, the most common respiratory virus on the planet.
Our goal is to disrupt the COPD treatment paradigm by targeting the upstream cause of acute respiratory exacerbations -- not accept the status quo of managing the long term downstream consequences like chronic inflammation, hospitalizations and even death.
- Industry Biotechnology Research
- Website https://www.altesabio.com/
- LinkedIn https://www.linkedin.com/company/altesa-biosciences/
Mantis Space | $10,000,000 | (Mar 13, 2026)
Monteris Medical | $28,000,000 | (Mar 13, 2026)
Gumloop | $50,000,000 | (Mar 13, 2026)
Combat Medical Ltd | $3,472,639 | (Mar 13, 2026)
Qurrent | $15,000,000 | (Mar 13, 2026)
Waiv, formerly Owkin Dx | $33,000,000 | (Mar 13, 2026)
Carefam | $14,500,000 | (Mar 13, 2026)
Option Circle | $3,000,000 | (Mar 12, 2026)
AgentMail (YC S25) | $6,000,000 | (Mar 12, 2026)